Milestone on Schedule
Tuesday July 5, 8:31 am ET
LAVAL, QC, July 5 /PRNewswire-FirstCall/ - Neurochem Inc. ... announced today the completion of recruitment of the 950 patients with mild-to- moderate Alzheimer's Disease (AD) for its North American Phase III clinical trial for Alzhemed(TM), the Company's investigational product candidate for the treatment of AD. The trial is being conducted in 51 U.S. and 17 Canadian clinical centers across North America. The Company has completed the selection of sites for a similarly sized Phase III clinical trial in Europe and expects to begin patient recruitment in the fall of 2005.
[ ... Read the full press release ... ]
From the Neurochem website:
Alzhemed™ is an orally administered, small organic molecule that has been specifically designed to modify the course of AD through its anti-amyloid activity. As part of a "disease modifying" novel class of product candidates, Alzhemed™ is expected to act at two levels: in preventing and stopping the formation and the deposition of amyloid fibrils in the brain and in binding to soluble A[beta] protein to reduce the amyloid-induced toxicity on neuronal and brain inflammatory cells associated with amyloid build-up in AD."
Anthony H. Risser
neuroscience | neuropsychology | brain | alzheimer disease